IPO News Archive

Clovis Oncology prices IPO at $13, at low end of the range

11/15/11


Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, raised $130 million by offering 10 million shares at $13. It had originally filed to offer 9.3 million shares at a price range of $13 to $15. Clovis Oncology, Inc. plans to list on the NASDAQ under the symbol CLVS. J.P. Morgan and Credit Suisse acted as lead managers on the deal.

Keywords/Tickers: CLVS
Related Links: Recently Priced IPOs
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest